Device Trial Radar · NCT03811171
Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study
Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Aug 20, 2019
Primary completion
Jan 30, 2027
Study completion Mar 30, 2027
Sponsor
- Lead sponsor
- SonoMotionNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Jan 22, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, multi-center, single-arm (non-randomized) study to assess the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave technology. Up to 30 subjects will be included. The procedure will be performed in a hospital surgical environment as an outpatient (without being admitted) or in a non-surgical environment such as a clinic or office procedure room. The procedure will be performed under varying levels of anesthesia ranging from no anesthesia to general anesthesia (fully asleep). Stones will be limited to ≤ 10 mm for lower pole stones and ≤ 20 mm everywhere else. Safety will be measured by the self-reported occurrences of adverse events, unplanned emergency department or clinic visits, and the need for further intervention. Fragmentation will be measured by self-reported stone passage and a comparison of computed tomography (CT) images before and after the procedure.
Conditions
- Renal Calculi
- Urinary Calculi
Interventions
Break Wave extracorporeal lithotripsyDevice
The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness Outcome - Stone FragmentationTime frame: 12 weeks post-treatment
- Primary Safety Outcome - Hematoma, urinary tract sepsis, or cardiac arrythmiaTime frame: 12 weeks post-treatment
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
University of California San Diego Health
San Diego, California · Completed
University of California, San Francisco
San Francisco, California · Completed
University of Washington Medical Center
Seattle, Washington · Completed
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.